Seroprevalence of Human T-lymphotropic virus type-1 and -2 infections among first-time United States Blood Donors 2000-2009

Chang, Yun Brenda; Kaidarova, Zhanna; Hindes, Daniel; Bravo, Marjorie; Kiely, Nancy; Kamel, Hany; Dubay, Denise; Hoose, Barbara; Murphy, Edward L.

doi:10.1186/1742-4690-11-s1-p61

Cited by 2 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The most notable epidemiological study by Murphy et al screened 1.7 million blood bank donors in 1999 and identified 156 HTLV-1+ and 384 HTLV-2+ PLHTLV in the United States. In this study, HTLV-1 was associated with black ethnicity and HCV seropositivity, and HTLV-2 infection was associated with a distinct birth cohort (age 30-49 years), female sex, black and Hispanic ethnicity, and HCV seropositivity (Murphy et al, 1999;Chang et al, 2014).…”

Section: Introductionmentioning

confidence: 60%

Clinical characteristics and outcomes of infection with human T-lymphotropic virus in a non-endemic area: a single institution study

et al. 2023

View full text Add to dashboard Cite

IntroductionUnderstanding of human T-lymphotropic virus (HTLV) remains largely based on epidemiologic and clinical data from endemic areas. Globalization has resulted in migration of persons living with HTLV (PLHTLV) from endemic to non-endemic areas, and a rise of HTLV infection in the United States. Yet, due to the historical rarity of this disease, affected patients are often under- and mis-diagnosed. Thus, we sought to characterize the epidemiology, clinical features, comorbidities, and survival of HTLV-1- or HTLV-2-positive individuals identified in a non-endemic area.MethodsOur study was a single institution, retrospective case–control analysis of HTLV-1 or HTLV-2 patients between 1998 and 2020. We utilized two HTLV-negative controls, matched for age, sex, and ethnicity, for each HTLV-positive case. We evaluated associations between HTLV infection and several hematologic, neurologic, infectious, and rheumatologic covariates. Finally, clinical factors predictive of overall survival (OS) were assessed.ResultsWe identified 38 cases of HTLV infection, of whom 23 were HTLV-1 and 15 were HTLV-2 positive. The majority (~54%) of patients in our control group received HTLV testing for transplant evaluation, compared to ~24% of HTLV-seropositive patients. Co-morbidities associated with HTLV, hepatitis C seropositivity were higher in HTLV-seropositive patients compared to controls (OR 10.7, 95% CI = 3.2–59.0, p < 0.001). Hepatitis C and HTLV co-infection resulted in decreased OS, compared to no infection, hepatitis C infection alone, or HTLV infection alone. Patients with any cancer diagnosis and HTLV infection had worse OS compared to patients with cancer or HTLV alone. HTLV-1 positive patients had lower median OS compared to HTLV-2 patients (47.7 months vs. 77.4 months). In univariate analysis, the hazard for 1-year all-cause mortality was increased among patients with HTLV-seropositivity, adult T-cell leukemia, acute myelogenous leukemia, and hepatitis C infection. When corrected, multivariate analysis showed that HTLV seropositivity was no longer associated with 1 year all-cause mortality; however association with AML and hepatitis C infection remained significant.ConclusionHTLV-seropositivity was not associated with increased 1 year mortality in multivariate analysis. However, our study is limited by our small patient sample size, as well as the biased patient control population due to selection factors for HTLV testing.

show abstract

Section: Introductionmentioning

confidence: 60%

Clinical characteristics and outcomes of infection with human T-lymphotropic virus in a non-endemic area: a single institution study

et al. 2023

View full text Add to dashboard Cite

show abstract

“…USA: Chang et al . reported on the prevalence of HTLV among 2 million first-time, United States blood donors during 2000 – 2009 [ 104 ]. A total of 104 (5 per 10 5 ) had HTLV-1 antibodies and 300 (14.7 per 10 5 ) had HTLV-2 antibodies.…”

Section: Introductionmentioning

confidence: 99%

Conference Highlights of the 16th International Conference on Human Retrovirology: HTLV and Related Retroviruses, 26–30 June 2013, Montreal, Canada

et al. 2014

Self Cite

View full text Add to dashboard Cite

The 16th International Conference on Human Retrovirology: HTLV and Related Retroviruses was held in Montreal, Québec from June 26th to June 30th, 2013 and was therefore hosted by a Canadian city for the first time. The major topic of the meeting was human T-lymphotropic viruses (HTLVs) and was covered through distinct oral and poster presentation sessions: clinical research, animal models, immunology, molecular and cellular biology, human endogenous and emerging exogenous retroviruses and virology. In this review, highlights of the meeting are provided by different experts for each of these research areas.

show abstract

Seroprevalence of Human T-lymphotropic virus type-1 and -2 infections among first-time United States Blood Donors 2000-2009

Cited by 2 publications

References 0 publications

Clinical characteristics and outcomes of infection with human T-lymphotropic virus in a non-endemic area: a single institution study

Clinical characteristics and outcomes of infection with human T-lymphotropic virus in a non-endemic area: a single institution study

Conference Highlights of the 16th International Conference on Human Retrovirology: HTLV and Related Retroviruses, 26–30 June 2013, Montreal, Canada

Contact Info

Product

Resources

About